This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chiesi Farmaceutici S.p.A.
Drug Names(s): Zileuton CR (controlled release) tablets
All historical revenue for Zyflo IR and Zyflo CR is recorded under Zyflo IR.
Zileuton is an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid.
Critical Therapeutics and Abbott
In December 2003, Critical Therapeutics (CT) acquired an exclusive worldwide license from Abbott to develop, make, use and sell controlled-release and intravenous formulations of Zyflo for all clinical indications, except for the treatment of children under age seven and use in cardiovascular and vascular devices. This license included an exclusive sublicense of Abbotts rights in proprietary controlled-release technology originally licensed to Abbott by Jagotec AG, a subsidiary of SkyePharma.
In consideration for the license, CT paid Abbott an initial $1.5 million license fee and agreed to make aggregate milestone payments of up to $13.0 million to Abbott upon the achievement of various development and commercialization milestones, including the completion of the technology transfer from Abbott to CT, filing and approval of a product in the United States and specified minimum net sales of licensed products. In addition, CT agreed to pay...See full deal structure in Biomedtracker
Partners: AbbVie Inc. Vectura Group Mylan Inc. Vansen Pharma Inc.
Zyflo CR News
Additional information available to subscribers only: